XORTX Therapeutics Inc. (XRTX.V)
Develops drugs to treat kidney disease and gout caused by excess uric acid.
2.84+0.00%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-43.2%
The outlook
XRTX trades at $2.84, well below both its 50- and 200-day moving averages, signaling downward momentum. The stock sits near its 52-week low, having recovered just 6% from that bottom. Analyst coverage appears thin, and current market positioning leans decidedly bearish.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range6% of the way from its 52-week low to high
Market cap
$4.9M
52-wk high
9.85
52-wk low
2.43
50-day avg
3.01
200-day avg
3.55
Trailing P/E
—